TFX:NYE-Teleflex Incorporated (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 246.05

Change

+3.32 (+1.37)%

Market Cap

USD 6.61B

Volume

0.29M

Analyst Target

USD 426.10
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-2.77 (-1.18%)

USD 67.65B
ALC Alcon AG

-1.46 (-1.48%)

USD 48.64B
RMD ResMed Inc

-0.89 (-0.35%)

USD 35.98B
BAX Baxter International Inc

-0.45 (-1.12%)

USD 20.54B
AVTR Avantor Inc

-0.33 (-1.21%)

USD 18.49B
ATR AptarGroup Inc

+0.04 (+0.03%)

USD 10.16B
BLCO Bausch + Lomb Corp

+0.76 (+4.27%)

USD 6.26B
STVN Stevanato Group SpA

-0.21 (-1.09%)

USD 5.62B
WRBY Warby Parker Inc

-0.12 (-0.80%)

USD 1.57B
INFU InfuSystems Holdings Inc

-0.09 (-1.38%)

USD 0.14B

ETFs Containing TFX

RSPH Invesco S&P 500® Equal.. 1.75 % 0.00 %

-0.16 (-0.49%)

USD 1.02B
QRH:CA 0.00 % 1.20 %

N/A

N/A
OUSM 0.00 % 0.48 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.32% 47% F 24% F
Dividend Return 0.55% 33% F 11% F
Total Return -0.77% 47% F 22% F
Trailing 12 Months  
Capital Gain 15.27% 58% F 60% D-
Dividend Return 0.80% 33% F 9% A-
Total Return 16.07% 58% F 53% F
Trailing 5 Years  
Capital Gain -25.70% 27% F 19% F
Dividend Return 2.16% 14% F 6% D-
Total Return -23.54% 27% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -8.96% 16% F 9% A-
Dividend Return -8.52% 16% F 8% B-
Total Return 0.44% 33% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 18.78% 79% B- 55% F
Risk Adjusted Return -45.38% 11% F 7% C-
Market Capitalization 6.61B 64% D 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.90 60% 15%
Price/Book Ratio 2.55 64% 34%
Price / Cash Flow Ratio 22.77 36% 14%
Price/Free Cash Flow Ratio 20.97 31% 16%
Management Effectiveness  
Return on Equity 6.03% 69% 46%
Return on Invested Capital 7.17% 71% 58%
Return on Assets 3.27% 64% 60%
Debt to Equity Ratio 38.90% 55% 66%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector